{"id":"NCT01276639","sponsor":"Pfizer","briefTitle":"A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis","officialTitle":"Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2011-01-13","resultsPosted":"2014-09-19","lastUpdate":"2014-09-19"},"enrollment":901,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"Placebo/CP-690,550","otherNames":[]},{"type":"DRUG","name":"Placebo/CP-690,550","otherNames":[]}],"arms":[{"label":"Active Treatment 10 mg BID","type":"EXPERIMENTAL"},{"label":"ActiveTreatment 5 mg BID","type":"EXPERIMENTAL"},{"label":"Placebo Treatment","type":"PLACEBO_COMPARATOR"}],"summary":"The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.","primaryOutcome":{"measure":"Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"CP-690,550 5 mg","deltaMin":41.87,"sd":null},{"arm":"CP-690,550 10 mg","deltaMin":59.17,"sd":null},{"arm":"Placebo","deltaMin":9.04,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":74,"countries":["United States","Canada","Colombia","Germany","Hungary","Japan","Mexico","Poland","Serbia","Taiwan","Ukraine"]},"refs":{"pmids":["32816215","28751001","28396102","27538247","26149717"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921078&StudyName=A%20One-Year%20Study%20To%20Evaluate%20The%20Effects%20And%20Safety%20Of%20CP-690%2C550%20In%20Patients%20With%20Moderate%20To%20Severe%20Chronic%20Plaque%20Psoriasis"]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":363},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Blood creatine phosphokinase increased","Headache","Hypercholesterolaemia"]}}